Andrey J. Zarur, Ph.D. - Executive Chairman, Lumicell
Dr. Andrey Zarur is Co-Founder and Executive Chairman of Lumicell and Co-Founder, President & CEO of GreenLight Biosciences. Dr. Zarur has been active in early stage life sciences companies for over 20 years and has actively participated in the creation, IPO and M&A of over a dozen companies in the healthcare and clean energy sectors. Prior to starting GreenLight, Dr. Zarur was the Managing Partner at Kodiak Venture Partners, an early-stage, technology-driven venture fund based in Boston. He is also a co-founder and the Chairman of the Board of Directors of Solid Biosciences.
Dr. Zarur was named a Young Global Leader of the World Economic Forum in 2005, he is an Overseer of the Museum of Science in Boston and a Senior Lecturer at MIT Sloan School of Management. Dr. Zarur holds Masters’ of Science degrees and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, and undergraduate degrees from the National University of Mexico. Dr. Zarur is the author of several peer-reviewed articles and holds over 100 provisional and issued patents.
Kevin Hershberger - President & Chief Financial Officer
Kevin Hershberger is the Chief Financial Officer for Lumicell. He brings over 25 years of global financial management experience in a variety of life science products and manufacturing companies with an extensive range of expertise and leadership responsibilities. Kevin most recently served as Chief Financial Officer of ReWalk Robotics where he built out the company’s finance function and launched a partnership with Harvard University’s Wyss Institute encompassing a broad licensing and collaboration agreement to develop a Softsuit Exoskeleton. Prior to ReWalk, he held leadership roles with NxStage Medical as the Vice President of Finance, Controller, and Chief Accounting Officer. Kevin also served in a variety of finance leadership roles at Boston Scientific.
W. David Lee - President & Chief Scientific Officer
David was the founding CEO of Lumicell and is now the Chief Scientific Officer. After creating T2 Biosystems (NASDAQ TTOO) he returned to the MIT Koch Institute to develop new technology that would address breast cancer which was responsible of his wife’s death. Lumicell is the embodiment of that goal. David has over 35 years of experience translating innovation into commercial successes. As a senior vice president and managing director at Arthur D. Little (ADL), he directed the technology and product development division, one of three major ADL business lines, and personally managed over 50 development and commercialization programs during his tenure. David and his associates taught product development and commercialization skills to Fortune 500 companies including ABB, General Electric, Carrier and Analog Devices. He has a B.S. and an M.S. in Mechanical Engineering from Massachusetts Institute of Technology and completed the intensive Advanced Management Program at Harvard Business School.
Jorge Ferrer, Ph.D. - Senior Vice President of Clinical Research and Strategy
Jorge leads the company's research and development efforts including planning and overseeing the work with Lumicell’s academic collaborators, managing pre-clinical and clinical studies, and communicating and reporting to the FDA. During his post-doctoral with Dr. Moungi Bawendi at Massachusetts Institute of Technology, he developed the prototype of the Lumicell imaging system and conducted the proof-of-concept experiments in mice and dogs. He holds a Ph.D. in Biological Engineering from MIT, an M.S. in Mechanical Engineering from MIT and a B.S. in Mechanical Engineering from University of Puerto Rico Mayagüez. Prior to his post-graduate studies, Jorge worked as a Mechanical Design Engineer in the sensors and controls industry at Texas Instruments.
Sean Madden, Ph.D. - Senior Vice President of R&D, Oncology
Sean leads the refinement of Lumicell’s products and regulatory strategy to achieve FDA approval, the development of the next generation of Lumicell products, the management of Medical Affairs for ongoing and upcoming clinical trials, and the strategy, stewardship and growth of Lumicell’s intellectual property portfolio. Sean received his B.S. in chemistry from The University of Florida and his Ph.D. in analytical chemistry from The University of Arizona. He is an author on over 80 academic papers and an inventor on more than 10 patents and active applications. Sean has worked in biomedical measurements and medical devices for over 20 years in areas including drug discovery, non-invasive glucose detection, arterial blood gas sensing, cervical cancer screening, ophthalmology imaging, and interventional cardiology imaging. As Vice President of Research and Clinical at Infraredx, he developed the technology and trial strategy that led to unique and groundbreaking label claims for the detection of vulnerable plaque, commercialization and use in over 20,000 patients worldwide, and the acquisition of the company by Nipro Corporation.